Dr. Reckamp Discusses Heat Shock Proteins in Lung Cancer

Karen Reckamp, MD, MS
Published Online: Wednesday, August 17, 2011
Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, discusses the use of heat shock proteins in the treatment of lung cancer.

Reckamp explains that heat shock proteins act as chaperone proteins that permit oncoproteins to function. The proteins work as an alternative to inhibiting the tyrosine kinase pathway and are involved in multiple lung cancer related signalling pathways such as EGFR, RAS, ALK, and MET. Heat shock proteins can be used when resistance to other methods are developed.
Online CME Activities
Free CME from PER
Community Practice Connections™: 16th Annual International Lung Cancer Congress®
Community Practice Connections™: 14th Annual International Congress on the Future of Breast Cancer®
Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment Paradigm
Role of the Nurse in Facilitating Adherence to Oral Therapies in Oncology Practice
More Reading